Strategies to Reduce Acute Kidney Injury in Angioplasty

The title of this article leads us to think that we will find a list of things that we can do to reduce kidney injury. However, (unfortunately) sodium bicarbonate showed no benefit over saline and n-acetylcysteine showed no benefit over a placebo for the reduction of kidney damage after coronary angioplasty.

Sub análisis del EXCEL: angioplastia vs cirugía en insuficiencia renal crónicaAmong the protective measures most frequently tested are endovenous sodium bicarbonate and oral n-acetylcysteine, both with conflicting results.

 

The PRESERVE (Prevention of Serious Adverse Events Following Angiography) trial used a 2 × 2 factorial design and randomized 5177 patients with stage III or IV renal insufficiency requiring angiography to 1.26% sodium bicarbonate or 0.9% sodium chloride and n-acetylcysteine or placebo for 5 days. The primary endpoint was a composite of death, need for dialysis, or persistent renal insufficiency at 90 days. Contrast-associated acute kidney injury was a secondary endpoint.


Read also: Contrast Induced Kidney Injury, Infamous Problem with No Magical Solutions.


A total of 1161 study patients underwent coronary angioplasty. The mean glomerular filtration rate was 50.7 mL/min/1.73 m2 and 82% of the population had a history of diabetes.

 

The primary endpoint occurred in 2.6% of patients who received sodium bicarbonate vs. 4% of patients who received saline (p = 0.41) and in 3.8% of patients who received n-acetylcysteine vs. 2.8% of patients who received a placebo (p = 0.29). There were no significant differences among groups as regards the incidence of contrast-associated kidney injury.

 

Conclusion

Among patients with chronic kidney disease who underwent angioplasty, there was no benefit of sodium bicarbonate over regular saline or of n-acetylcysteine over placebo for the prevention of contrast-associated kidney injury.

 

Original title: Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes Following Percutaneous Coronary Intervention. A Subgroup Analysis of the PRESERVE Trial.

Reference: Santiago Garcia et al. J Am Coll Cardiol Intv 2018;11:2254-61.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....